Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Kalaris Therapeutics Inc. (KLRS) had Free Cash Flow per Share of $-2.53 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-43.44M |
|
-- |
|
-- |
|
$46.15M |
|
$-46.15M |
|
$2.71M |
|
$-43.44M |
|
$-43.44M |
|
$-43.44M |
|
$-43.44M |
|
$-43.44M |
|
$-43.44M |
|
$-46.15M |
|
$-46.54M |
|
15.27M |
|
15.27M |
|
$-2.85 |
|
$-2.85 |
|
| Balance Sheet Financials | |
$118.81M |
|
-- |
|
$2.93M |
|
$121.74M |
|
$9.71M |
|
-- |
|
$33.21M |
|
$42.92M |
|
$78.81M |
|
$78.81M |
|
$78.81M |
|
22.90M |
|
| Cash Flow Statement Financials | |
$-38.37M |
|
$-19.72M |
|
$155.01M |
|
$1.64M |
|
$98.55M |
|
$96.91M |
|
$1.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-38.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-55.11% |
|
-55.11% |
|
-35.68% |
|
-55.11% |
|
$3.44 |
|
|
Free Cash Flow per Share |
$-2.53 |
$-2.51 |
|